Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 3/20 | 0.40 |
| ▸ | AKT1 | P31749 | 1/20 | 0.38 |
| ▸ | TLR2 | O60603 | 2/20 | 0.35 |
| ▸ | TLR1 | Q15399 | 2/20 | 0.35 |
| ▸ | P2RY12 | Q9H244 | 3/20 | 0.33 |
| ▸ | GLP1R | P43220 | 8/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
| ▸ | MGLL | Q99685 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19903796 | 1.00 | PLK1 (0.40) | PLK1AKT1TLR2TLR1P2RY12 | |
| SCHEMBL24175784 | 0.93 | AKT1 (0.40) | PLK1AKT1TLR2TLR1P2RY12 | |
| SCHEMBL16273727 | 0.88 | AKT1 (0.41) | PLK1AKT1P2RY12TDP1 | |
| SCHEMBL15919172 | 0.88 | AKT1 (0.41) | PLK1AKT1P2RY12TDP1 | |
| SCHEMBL31648515 | 0.86 | MGLL (0.41) | PLK1AKT1TLR2TLR1MGLL | |
| SCHEMBL16329598 | 0.86 | GLP1R (0.45) | PLK1AKT1TLR2TLR1GLP1R | |
| SCHEMBL19541913 | 0.86 | GLP1R (0.45) | PLK1AKT1TLR2TLR1GLP1R | |
| SCHEMBL22025537 | 0.86 | GLP1R (0.45) | PLK1AKT1TLR2TLR1GLP1R | |
| SCHEMBL16329597 | 0.86 | GLP1R (0.45) | PLK1AKT1TLR2TLR1GLP1R | |
| SCHEMBL26445412 | 0.86 | GLP1R (0.45) | PLK1AKT1TLR2TLR1GLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10947289-B2 | Glyco-modified atrial natriuretic peptide | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-03-16 | — | — | US | disclosed |
| US-20210040170-A1 | GLYCO-MODIFIED ATRIAL NATRIURETIC PEPTIDE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2021-02-11 | — | — | US | disclosed |
| EP-2949665-B1 | GLYCOSYLATION ATRIAL NATRIURETIC PEPTIDE | DAIICHI SANKYO CO LTD (JP) | 2018-02-28 | — | — | EP | disclosed |
| US-20160017015-A1 | GLYCO-MODIFIED ATRIAL NATRIURETIC PEPTIDE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-01-21 | — | — | US | disclosed |
| US-20160017015-A1 | GLYCO-MODIFIED ATRIAL NATRIURETIC PEPTIDE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-01-21 | — | — | US | disclosed |
| EP-2949665-A1 | GLYCOSYLATION ATRIAL NATRIURETIC PEPTIDE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-12-02 | — | — | EP | disclosed |
| WO-2014115797-A1 | GLYCOSYLATION ATRIAL NATRIURETIC PEPTIDE | 第一三共株式会社 (JP) | 2014-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10947289-B2 | Glyco-modified atrial natriuretic peptide | NPPA, NPR1, NPR3 | PLK1 4856/4885AKT1 1794/4885TLR2 2128/4885 |
| US-20210040170-A1 | GLYCO-MODIFIED ATRIAL NATRIURETIC PEPTIDE | NPPA, NPR1, NPR3 | PLK1 4856/4885AKT1 1794/4885TLR2 2128/4885 |
| US-20160017015-A1 | GLYCO-MODIFIED ATRIAL NATRIURETIC PEPTIDE | NPPA, NPR1, NPR3 | PLK1 4856/4885AKT1 1794/4885TLR2 2128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.